When a radiation oncologist recommends radiation therapy, many patients assume there is only one kind. In fact, radiation has evolved considerably, and one of the most significant developments of the past three decades is proton therapy. Understanding the difference between conventional photon radiation and proton therapy does not require a physics degree — but it does require a clear explanation, because the choice can have real consequences for both effectiveness and long-term side effects.

How Conventional Radiation (Photon/X-Ray) Works

Standard radiation therapy uses high-energy X-rays, which are packets of energy called photons. When a beam of photons enters the body aimed at a tumor, it deposits radiation energy along its entire path — entering the skin, passing through healthy tissue, hitting the tumor, and then continuing through the body and out the other side. Modern techniques like Intensity-Modulated Radiation Therapy (IMRT) and stereotactic radiosurgery (SBRT/SRS) use multiple precisely angled beams that converge on the tumor, which reduces but does not eliminate the dose to surrounding healthy tissue. The physics of photons means some “exit dose” is unavoidable: radiation is deposited both before and after the tumor target.

How Proton Therapy Works — and What the Bragg Peak Means for You

Proton therapy uses protons — the positively charged particles at the center of hydrogen atoms — accelerated to roughly 60% of the speed of light inside a large machine called a cyclotron or synchrotron. Protons behave very differently from photons in tissue. As a proton beam travels through the body, it deposits relatively little energy on the way in, then releases the vast majority of its energy in a sharp burst at a predictable stopping point. This burst is called the Bragg peak. After the Bragg peak, energy deposition drops almost to zero — there is virtually no exit dose. Physicists and physicians can tune the energy of the beam to position the Bragg peak precisely at the tumor’s depth. The practical result: surrounding healthy tissue, including organs in front of the tumor, receives meaningfully less radiation than with photon techniques, and tissue behind the tumor receives almost none.

This physics advantage matters most when the tumor sits close to structures that are especially sensitive to radiation damage — the spinal cord, brainstem, optic nerves, salivary glands, heart, lungs, or a developing child’s brain. The advantage is smaller when a tumor is located where there is little critical anatomy nearby.

Where Proton Therapy Is Established vs. Still Being Studied

Proton therapy has strong clinical evidence and is widely considered a preferred or appropriate standard option in several settings. Pediatric brain tumors represent one of the clearest use cases: children’s developing brains are extremely sensitive to radiation scatter, and reducing exposure significantly lowers rates of cognitive impairment, growth hormone deficiency, and secondary cancers that can emerge years later. Head and neck cancers — particularly those near the salivary glands, spinal cord, and brainstem — are another well-supported indication, as sparing those structures reduces rates of xerostomia (dry mouth), difficulty swallowing, and nerve damage. Ocular melanoma and other tumors of the eye are treated with proton therapy at specialized centers, often preserving vision that surgery would sacrifice. Prostate cancer, particularly when treated with high doses, is a setting where long-term data show proton therapy is at least equivalent in cancer control with comparable or reduced rectal and bladder toxicity compared to photon IMRT.

Other cancer types are under active investigation but do not yet have definitive randomized trial data establishing superiority. Breast cancer in left-sided cases carries a well-known risk of cardiac exposure with photon radiation; proton therapy can reduce that dose substantially, but whether this translates into measurable reductions in long-term cardiac events is still being studied in trials. Lung cancer, particularly centrally located tumors near the heart and major vessels, is another active area — preliminary data look promising, but results vary by technique and center experience. Esophageal, liver, and pancreatic cancers are also under investigation. This does not mean proton therapy is experimental in these settings — many centers treat them routinely — but it does mean the evidentiary standard is not as settled as it is for pediatric CNS tumors or head and neck cancer.

Side Effects: What the Difference Looks Like in Practice

Side effects from both modalities depend heavily on the tumor site, dose, technique, and the individual patient. That said, the lower integral dose of proton therapy (meaning less total radiation deposited in the body overall) generally translates to lower rates of certain long-term toxicities, especially in pediatric patients and in adults treated near critical structures. In head and neck cancer patients, proton therapy is associated with reduced rates of severe dry mouth and feeding tube dependence. In left-sided breast cancer, heart doses can be dramatically lower. For prostate cancer, bowel toxicity rates may be marginally reduced. Acute side effects during treatment — fatigue, local skin reactions, mucositis in head and neck cases — are often similar between modalities. One side effect to be aware of with proton therapy: in some tumor locations, particularly near air cavities like the sinuses or lungs, the proton beam can be subject to range uncertainty, which centers manage with careful planning but which can affect dose distribution. Proton therapy is not inherently gentler in every dimension — it is more targeted, which is the goal.

How to Pursue Proton Therapy: Candidacy, Questions, and Insurance

If you have been recommended radiation therapy, start by asking your radiation oncologist directly: “Is proton therapy a clinically appropriate option for my diagnosis, and if not, why not?” A radiation oncologist who does not practice at a proton center may be less familiar with current indications, so asking for a second opinion at a proton center is entirely reasonable and something proton centers offer routinely. Questions worth bringing to any radiation oncology consultation include: What is the total dose to my [heart/spinal cord/salivary glands/optic nerves]? How does that compare with a proton plan? What are the expected short-term and long-term side effects of each approach? What does the published evidence say for my specific diagnosis and stage? Is there an active clinical trial for which I might qualify?

Insurance coverage for proton therapy has improved substantially but remains inconsistent. Medicare covers proton therapy for most indications for which it is considered medically appropriate. Commercial insurers vary widely; some cover it broadly, others require peer-reviewed evidence for each indication, and some deny it as experimental for certain tumor sites. If your insurer denies coverage, you have the right to appeal. A proton center’s insurance team will typically assist with pre-authorization and appeal letters — this is a routine part of their process, not an unusual request. Appeal letters should include peer-reviewed literature supporting the indication, a letter of medical necessity from your physician, and documentation of the dose comparison between photon and proton plans. Do not accept a first denial as final; many appeals succeed, particularly when supported by strong clinical documentation.